Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations.
McDonald E, Swoboda DM.
Semin Hematol. 2024 Dec;61(6):465-469. doi: 10.1053/j.seminhematol.2024.11.001. Epub 2024 Nov 20.
Paroxysmal nocturnal haemoglobinuria in pregnancy--not to be confused with pre-eclampsia or HELLP syndrome. Case report and literature review.
Higgins SP, McMahon LP, Brennecke SP.
J Obstet Gynaecol. 2004 Jan;24(1):83-5. doi: 10.1080/01443610310001627155.
Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.
Fracchiolla NS, Sciumè M, Dambrosi F, Guidotti F, Ossola MW, Chidini G, Gianelli U, Merlo D, Cortelezzi A.
BMC Cancer. 2017 Jun 23;17(1):442. doi: 10.1186/s12885-017-3436-9.
[Pregnancy in paroxysmal nocturnal hemoglobinuria: from survival to life].
Vinogradova MA, Kulagin AD, Shmakov RG.
Ter Arkh. 2022 Aug 12;94(7):859-864. doi: 10.26442/00403660.2022.07.201714.
Paroxysmal nocturnal hemoglobinuria in pregnancy.
Bjørge L, Ernst P, Haram KO.
Acta Obstet Gynecol Scand. 2003 Dec;82(12):1067-71. doi: 10.1046/j.1600-0412.2003.00337.x.
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD, Kim SW, Suh CW, Kim EK, Bahng HS, Jeong YH, Park IG, Kim WK, Kim SH, Suh EJ, Park CJ, Ji HS, Lee JS.
J Korean Med Sci. 2002 Aug;17(4):555-9. doi: 10.3346/jkms.2002.17.4.555.
[Treatment of paroxysmal nocturnal hemoglobinuria (PNH)].
Chrobák L, Dulícek P, Zák P.
Vnitr Lek. 2001 Dec;47(12):880-6.
How I treat paroxysmal nocturnal hemoglobinuria.
Brodsky RA.
Blood. 2009 Jun 25;113(26):6522-7. doi: 10.1182/blood-2009-03-195966. Epub 2009 Apr 16.
[Pregnancy: a possible etiology of pyoderma gangrenosum. A case report and review of the literature].
Sergent F, Joly P, Gravier A, Verspyck E, Marpeau L.
J Gynecol Obstet Biol Reprod (Paris). 2002 Sep;31(5):506-11.
[Hypoplastic myelodysplastic syndrome progressing to acute myelocytic leukemia (M2) after treatment with G-CSF and immunosuppressants].
Miyata A, Deguchi S, Kikuchi T, Osada T, Sanada H.
Rinsho Ketsueki. 1998 Jun;39(6):453-9.
